"The public is very concerned and eagerly anticipating the fact that dengue fever, an epidemic that has plagued impoverished communities for decades, can finally be 'solved with a single injection'," Valesca Mión, health inspector of the Guarulhostra Quelidad community vaccination site in São Paulo state, told reporters on the 26th. She added that she had been notified that, with increased production capacity, the vaccination program would be expanded to cover the entire population.

Brazil's Ministry of Health recently announced that Brazil will begin single-dose dengue fever vaccination by the end of January 2026, with the first batch of 300,000 doses of dengue vaccine developed by the Butantan Institute already delivered. The Brazilian government has initially allocated 368 million reais, planning to provide a total of 3.9 million doses to the public healthcare system. The Butantan Institute is expected to deliver another 1 million doses by the end of January 2026.

According to the Butantan Institute in Brazil, this domestically produced vaccine, named Butantan-DV, took over a decade to develop and is currently the only approved single-dose dengue vaccine globally. As a quadrivalent dengue vaccine, it protects against all four types of dengue fever and is suitable for people aged 12 to 59. Clinical studies show that it has a protective efficacy of 74.7% against overall dengue cases, a 91.6% effectiveness rate against severe cases, and a 100% effectiveness rate for hospitalizations due to dengue fever.

Brazil will conduct pilot vaccination programs in Botucatu, São Paulo state, and Maranguape, Ceará state. The first batch of vaccines will be prioritized for primary healthcare workers, including community health workers, endemic disease control personnel, and healthcare workers providing door-to-door services.

It is understood that, to increase production capacity, the vaccine is being manufactured in collaboration between Brazil's Butantan Institute and China's WuXi Biologics . Through the implementation of the Brazilian Ministry of Health's Local Development and Innovation Program, it is projected that approximately 30 million doses of the vaccine will be available by the second half of 2026.

An article published on the website of the Butantan Institute in Brazil quoted Daniela Ventini, the technical manager in charge of liaising with Chinese companies, as saying: "(The Brazil-China cooperation) will significantly improve our vaccine delivery capacity and accelerate the pace at which people can obtain essential products."

Last year, Brazil saw a significant increase in dengue fever cases. Data released by the Brazilian Ministry of Health's Vector-borne Virus Surveillance Task Force shows that as of December 26, 2025, Brazil has reported a 75% decrease in suspected dengue fever cases compared to the same period last year, with 1,660,190 cases still reported. The Brazilian Ministry of Health stated that vaccination will be combined with mosquito-borne disease control, environmental management, and public health education to continuously consolidate the achievements in dengue fever prevention and control.

https://finance.eastmoney.com/a/202512273603594394.html